Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

The drug is now available for prescription in New Zealand but there are clouds to go along with the silver linings - such as ...

Does using Ozempic cause brain fog? It depends on who you ask. This article takes a closer look at what’s going on with ...

Weight-loss jabs will be made available to the poorest who have the highest need, the Government has said in the NHS 10-year ...

Medically reviewed by Karina Tolentino, RD The Aperol spritz has gained a reputation for being a healthier alternative to other cocktails. However, this drink, made with Aperol liqueur and prosecco ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

For weight loss, weight management, and overall wellness, focus on eating healthy foods, like high-protein meals, legumes, ...

Q: I have been caring for my 75-year-old husband with dementia for the past four years (I am 72), and I’m at my wits’ end. Suggestions? — Carey T., Joplin, ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead to the loss of vision, according to the EU medicines regulator.

Wegovy belongs to a group of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. It contains the active ingredient semaglutide, which mimics the activity of our brain’s natural GLP-1.